BZW2 is a transcriptional regulator common in UC and lung cancer, consistently co-expressed in a statistically significant manner in lung cancer [4,10] through glycolysis-mediated IDH3G lactylation, offering a theoretical basis for the targeted treatment of LUAD with glycolysis and HLA [159], and which shows local genetic variations of IBD effecting risk prediction in genome-wide association studies [160]. The gene discussed is IDH3G; the disease is lung carcinoma.